Neuroscience
Selective action of ifenprodil at the N-methyl-D-aspartate receptor probed
Published in Pharma Investments, Ventures and Law Weekly, November 19th, 2006
"Selective antagonism of NMDA 2B subunit containing receptors has been suggested to have potential therapeutic application for multiple CNS disorders. The amino terminal NR2B residues 1 to 282 were found to be both necessary and sufficient for the binding and function of highly NR2B subunit specific antagonists like ifenprodil and CP-101,606," wrote T.W. Rosahl and colleagues, Merck & Co.
"Using a genetic approach in mice, we successfully replaced the murine NR2B gene...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Business & Finance
HealthSouth announces stockholder approval of reverse stock split - Dental Research
Danish agency makes statement about tooth whitening products - End-of-Life Issues
Initiative provides advance care directives to ethnically and culturally diverse communities - Finance
Cyberkinetics closes $10 million private placement - Finance
MedicalCV, Inc. announces $2.5 million private financing - Legal Issues
Align Technology and OrthoClear complete definitive agreement - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
